In the latest trading session, Bristol Myers Squibb (BMY) closed at $45.10, marking a +2.15% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.41%. Elsewhere, the Dow gained 0.18%, while the tech-heavy Nasdaq added 0.31%.
The stock of biopharmaceutical company has fallen by 6.42% in the past month, lagging the Medical sector's loss of 0.38% and the S&P 500's gain of 3.15%.
Market participants will be closely following the financial results of Bristol Myers Squibb in its upcoming release. The company plans to announce its earnings on October 30, 2025. The company is predicted to post an EPS of $1.65, indicating a 8.33% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $11.77 billion, indicating a 1.03% downward movement from the same quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $6.5 per share and revenue of $47.31 billion. These totals would mark changes of +465.22% and -2.06%, respectively, from last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Bristol Myers Squibb. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. As of now, Bristol Myers Squibb holds a Zacks Rank of #3 (Hold).
In terms of valuation, Bristol Myers Squibb is presently being traded at a Forward P/E ratio of 6.79. This denotes a discount relative to the industry average Forward P/E of 18.79.
We can also see that BMY currently has a PEG ratio of 2.26. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.68 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 78, placing it within the top 32% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol Myers Squibb Company (BMY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
